PMID

Data

Article Title

Organization

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.

Shandong University

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Novartis Institutes For Biomedical Research

Selective inhibitors of protein methyltransferases.

Icahn School Of Medicine At Mount Sinai

Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.

University Of North Carolina At Chapel Hill

A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.

Baylor College Of Medicine

Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.

Entremed

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.

TBA

Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.

Baylor College Of Medicine

Oncoepigenomics: making histone lysine methylation count.

TBA

Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.

Masaryk University

Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.

Csir-Indian Institute Of Chemical Biology

Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.

Sapienza University Of Rome

Discovery of

China Pharmaceutical University

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.

China Pharmaceutical University

5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.

Chinese Academy Of Sciences

Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.

University Of Michigan Medical School

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Novartis Institutes For Biomedical Research

New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.

University College London

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

Novartis Institutes For Biomedical Research

High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide

Biokin

New Potent DOT1L Inhibitors for

Novartis Institutes For Biomedical Research

Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.

Punjabi University

Quinoline and quinolone dimers and their biological activities: An overview.

Zhejiang Ocean University

Why Some Targets Benefit from beyond Rule of Five Drugs.

Boston University

Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.

Chinese Academy Of Sciences

Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L.

Baylor College Of Medicine

Novel inhibitors of As(III) S-adenosylmethionine methyltransferase (AS3MT) identified by virtual screening.

Astrazeneca

Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.

University Of Science And Technology Of China

Preparation of 5'-deoxy-5'-amino-5'-C-methyl adenosine derivatives and their activity against DOT1L.

Shenyang Pharmaceutical University

Discovery of Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT).

Icahn School Of Medicine At Mount Sinai

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

Novartis Institutes For Biomedical Research

Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L.

Epizyme